Jane Street Group, LLC Ascendis Pharma A/S Call Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $1.45 Million - $1.96 Million	12,800 New	12,800 $1.91 Million
Q1 2022 May 17, 2022	BUY	$102.18 - $135.75 $8.1 Million - $10.8 Million	79,300 Added 1279.03%	85,500 $10 Million
Q4 2021 Feb 15, 2022	SELL	$127.1 - $169.66 $1.64 Million - $2.19 Million	-12,900 Reduced 67.54%	6,200 $834,000
Q3 2021 Nov 16, 2021	BUY	$112.67 - $176.92 $1.33 Million - $2.09 Million	11,800 Added 161.64%	19,100 $3.04 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $145,944 - $174,348	1,200 Added 19.67%	7,300 $960,000
Q1 2021 May 18, 2021	SELL	$124.92 - $173.33 $1.86 Million - $2.58 Million	-14,900 Reduced 70.95%	6,100 $786,000
Q4 2020 Feb 17, 2021	BUY	$151.2 - $182.76 $2.1 Million - $2.54 Million	13,900 Added 195.77%	21,000 $3.5 Million
Q3 2020 Nov 17, 2020	SELL	$134.29 - $154.32 $711,737 - $817,896	-5,300 Reduced 42.74%	7,100 $1.1 Million
Q2 2020 Aug 17, 2020	BUY	$110.87 - $156.01 $1.37 Million - $1.93 Million	12,400 New	12,400 $1.83 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.